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Abstract: Introduction: Sickle cell disease (SCD) is a genetically inherited, recessive mutation of the haemoglobin βS-
gene. Each year, over 300,000 babies are born with SCD, which will have a significant impact on their quality of life and 
average life expectancy. Currently, for SCD to be tested prenatally, foetal DNA is extracted by amniocentesis, chorionic 
villus sampling or cordocentesis, and then analysed by polymerase chain reaction (PCR), for instance. These 
procedures increase the risk of foetal miscarriage by less than 0.5%. SCD may, however, be tested non-invasively using 
cell-free foetal DNA (cffDNA), which is extracted from maternal blood plasma. In this study, the current accuracy of using 
cffDNA testing for non-invasive prenatal diagnosis (NIPD) of SCD will be shown. 
Methods: Using databases such as PubMed, Web of Science and Scopus, this study systematically reviewed existing 
studies pertaining to the use of cffDNA maternal blood samples for non-invasive prenatal testing (NIPT) or diagnosis 
(NIPD) for SCD in patients who were at risk of having a baby with SCD. The data collected from the systematic review of 
the studies was statistically analysed in the form of a meta-analysis, describing the proportion of correct diagnosis results 
for this method of prenatal testing. 
Results: Of over 3,600 papers identified from the database searches, only five studies contained data pertaining to the 
use of cffDNA for prenatal testing of SCD and conformed to the inclusion criteria set out by this study. Collectively, these 
data showed an average of 81.30% accuracy of diagnosis when using cffDNA to test for SCD, with 18.70% of foetuses 
incorrectly diagnosed. These data were compiled as a Forest Plot meta-analysis.  
Conclusion: CffDNA for non-invasive prenatal SCD diagnosis appears to have the potential to be an accurate technique 
for the testing of this genetic disease, despite not currently indicating a proportion of correct diagnosis results which 
would encourage the technique for clinical implementation. Whilst there are currently very limited data on the use of this 
technique for the specific testing of SCD, there is great opportunity for further research into the standardisation and 
clinical application of this procedure.  
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INTRODUCTION 
SCD is defined as a hereditary (autosomal 
recessive monogenic) haemoglobinopathy, which 
includes sickle cell anaemia (HbSS disease) and 
various compound heterozygous genotypes, for 
example, sickle cell HbSC disease or sickle cell β-
thalasaemia disease (HbSβthal) characterised by 
chronic haemolytic anaemia and vaso-occlusive 
complications. It is globally amongst the most common 
genetic disorders, affecting approximately 30 million 
people [1-3]. SCD is associated with high lifetime 
morbidity and premature mortality, as described in the 
most recent Global Burden of Disease study. 
Approximately 7% of the world’s populations are 
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healthy carriers of haemoglobinopathies, resulting in 
300,000 newborns severely affected with SCD annually 
[4].  
In South East London, close to 0.3% of newborns 
are affected by SCD, whereas the average in the 
United Kingdom is 0.05%, with SCD being the most 
common reason for invasive prenatal diagnostic 
testing, reporting approximately 350 cases each year 
[2, 5, 6].  
Due to the severity of this disease and the limited 
treatment options, prenatal diagnosis by invasive 
testing is offered in many countries as part of a national 
prevention programme, with a procedure-related risk of 
miscarriage being reported as 0.05% for chorionic villus 
sampling and <0.5% for amniocentesis [5, 7, 8], which 
are the current gold standards for prenatal testing, and 
are approximately 100% accurate [7]. 
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The discovery of cffDNA in maternal blood 
circulation has led to the possibility of NIPT or NIPD 
mitigating the invasive procedure-related risk of 
miscarriage [5, 7]. This discovery has been applied 
successfully for RhD genotype, trisomy 21, 13 and 18 
detection, as well as foetal sex determination (reporting 
96.6% sensitivity and 98.6% specificity using this 
technique) [9, 10]. CffDNA is detectable very early 
during pregnancy, with the mean quantity of cffDNA 
during the first and second trimesters being 
approximately 10% of the total amount of cell-free DNA 
[2]. SCD may be tested non-invasively, therefore, 
patients may favour this technique as, apart from being 
safe, it is also accurate [2, 11]. This systematic 
manuscript review was undertaken to ascertain the 
available data to determine whether using cffDNA for 
NIPD of SCD has a sensitivity and specificity that can 
match the gold standard and could, therefore, 
potentially be used in a clinical setting. 
METHODS 
Search Strategy  
A systematic review and meta-analysis was 
performed whilst adhering to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis 
guideline and Meta-Analysis of Observational Studies 
in Epidemiology criteria [12] and SEDATE guidelines 
[13]. This systematic review was registered apriori 
(Reference Number: CRD42016037239). The following 
databases were searched for previous work 
undertaken between January 1995 and April 2016. The 
databases researched were PubMed, Cochrane 
Library, Web of Science, Scopus, Google Scholar, 
Science Direct and Ovid (Limitations: research, 
reviews, author manuscripts); the search criteria are 
presented in Table 1. Abstracts and full text articles 
were assessed by two authors (LS and EON) in order 
to select the articles that met the inclusion criteria. 
Further detailed investigations of the relevant original 
and review articles were undertaken to identify 
applicable studies. There were no language 
restrictions. 
Study Selection 
The studies incorporated in the systematic review 
met the following criteria: 
• The study design was a cohort study; 
• The exposure of interest was pregnant women at 
risk of having a baby with SCD or sickle cell trait; 
• The studies contained specific data on the 
genetic testing of cffDNA from maternal plasma 
or serum, as part of an on-going study; 
• The studies performed a data comparison to the 
gold standard, or tested for the genotype at birth; 
• The selected studies describe results gained 
from each study compared to a control group, 
which presents as patients who are not at risk of 
having a SCD or sickle cell trait baby [14, 15]. 
Reviews, editorials, non-human studies, and 
published letters without data were excluded. No 
studies including data pertaining to twin studies using 
cffDNA for NIPD of SCD were included. 
Study Characteristics 
Study Outcome 
The aim of this study was to perform a systematic 
review and subsequent meta-analysis on NIPD of SCD. 
All publications retrieved as a result of the search 
Table 1: Key Phrases used for the Sophisticated Search of the Systematic Review, Determined by the Inclusion 
Criteria Presented in Study Selection Below 
“Sickle cell disease” and “foetal testing” 
“Sickle cell disease” and “prenatal” and “diagnosis” and “foetal blood” 
“Sickle cell disease” or “sickle cell anaemia” and “prenatal” and “diagnosis” and “non-invasive”  
“Sickle cell disease” and “prenatal” and “diagnosis” and “free foetal DNA” 
“Sickle cell disease” and “prenatal” and “diagnosis” and “non-invasive” and “free foetal DNA” 
“Sickle cell disease” and “detection” and “non-invasive” and “prenatal” and “cell-free DNA” 
“Sickle cell disease” or “sickle cell anaemia” and “antenatal” and “diagnostic” and “minimally invasive” and “free foetal DNA” 
“Sickle cell disease” and “prenatal” and “haemoglobinopathy” and “diagnosis” and “non-invasive” 
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strategies, previously outlined in the Study Selection, 
were systematically appraised to compile a list of 
manuscripts containing research data on the use of 
cffDNA for NIPD of SCD. A meta-analysis was then 
performed on the data retrieved from the final selection 
of manuscripts to determine the proportion of correct 
diagnosis results. Finally, a conclusion was drawn as to 
whether the level of accuracy and associated risk to the 
mother and foetus from tests using cffDNA technique 
should be recommended for clinical use, with regards 
to NIPD of SCD [15,16]. 
Intervention 
The intervention for each of the studies analysed in 
this review was the technique for prenatal non-invasive 
SCD diagnosis, in the form of cffDNA, which was 
extracted from a maternal blood sample and tested for 
the sickle cell mutation, for example, by PCR  
[2, 15, 16]. 
Comparator 
For each of the selected studies used in the meta-
analysis, the result of the diagnosis using cffDNA was 
compared to the gold standard of testing, being either 
amniocentesis or chorionic villus sampling. In some 
cases, genetic testing to confirm foetal genotype was 
assessed at birth, as a secondary determination [16]. 
Study Design 
The studies included in the meta-analysis were 
prospective cohort studies, therefore, the specific data 
on the genetic testing of cffDNA from maternal plasma 
or serum were collected as part of an on-going study, 
allowing for PCRs or single nucleotide polymorphism 
(SNP) analysis to be performed at the time of blood 
sampling. This was then followed up by comparison to 
the gold standard, or by testing of the genotype at birth. 
The results gained from each study were compared to 
a control group, which was presented as pregnant 
patients who were not at risk of having a SCD or sickle 
cell trait baby [14, 15]. 
Study Population 
The study population selected for this systematic 
review were pregnant women, of whom either 
themselves, the father of the foetus, or both parents 
were a SCD carrier or SCD patient [14, 16, 17]. 
Data Extraction 
 Due to the limited appropriate data retrieved from 
the systematic review, those papers which contained 
usable and relevant data to NIPD for SCD, whilst 
conforming to the restrictions outlined in Study 
Selection, were included in the meta-analysis. A total of 
3,631 papers were identified and screened following 
the search stage during the systematic review, to which 
only five papers could be applied to the Newcastle-
Ottawa Quality Assessment Scale (see Figure 1), as 
well as the QUADAS-II quality assessment guideline 
[18] (see Table 2), and, therefore, were included in the 
meta-analysis. The five studies described the relevant 
data retrieved from a total of 139 pregnant patients who 
were at risk of having a baby with SCD. 
Quality Assessment 
The manuscripts included in the systematic review 
were subjected to quality assessment scoring using the 
Newcastle-Ottawa Quality Assessment Scale for cohort 
studies [19] and the QUADAS-II assessment table, to 
determine the potential for any bias within the studies 
which were to be included in the meta-analysis. Those 
manuscripts to which the Newcastle-Ottawa Quality 
Assessment Scale could not be applied, due to the 
absence of relevant data, were excluded from the 
meta-analysis. Four papers and one abstract of a 
paper to which the quality assessment scale could be 
applied were used in the final data extraction stage. 
These manuscripts were studies by Cheung et al., 
(1996) [20], Barrett et al., (2012) [2], Phylipsen et al., 
(2012) [21], Fielding et al., (2013) [22] and Yenilmez et 
al., (2013) [23]. The papers were scored as low, 
medium or high quality according to the QUADAS-II 
assessment table, and out of 8* according to the 
Newcastle-Ottawa Quality Assessment Scale, by their 
relevance to the answers of questions under three 
subheadings:  
• Selection, whereby the study representatives, 
selection of participants, ascertainment and 
demonstration of exposure are determined;  
• Comparability, whereby the use and propriety of 
a control group is assessed;  
• Study Outcome, whereby the assessment of 
outcome, longevity of the study and follow up of 
the study are assessed. 
The study with the highest quality score was that by 
Phylipsen et al., (2013) [21], with 8*/8* (Medium 
QUADAS-II score). The study with the lowest score 
was the abstract of a paper by Fielding et al., (2013) 
[22] with 3*/8* (Low QUADAS-II score), as the abstract 
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contained little information which would allow for the 
generation of a quality assessment score and was, 
therefore, of low quality for the purposes of this study. 
Overall, the quality of the studies used in the data 
synthesis was of a satisfactory standard, therefore, 
showed little bias. The risk of bias across these papers 
could be increased by the omission of false positive or 
false negative data, as well as the data from the 
controls. If the data from the control group was 
inaccurate, then the data retrieved from method and 
subsequent results would be inaccurate. 
Statistical Analysis 
It was originally intended that the data retrieved as 
part of the systematic review would be presented in the 
form of a meta-analysis and a subsequent Forest Plot, 
in order to determine the sensitivity and specificity of 
the use for NIPD for the determination of foetal SCD. 
However, the lack of homogeneity between the 
independent studies due to the uses of differing 
methods and techniques between the studies [24], as 
well as the inability to distinguish between the  
true positive and true negative values from the data  
 
Figure 1: A flow diagram outlining the study selection process during the systematic paper review.  
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Table 2: A Table Detailing the Quality Assessment Scores and Criteria for the Five Studies from the Systematic 
Review which were Included in the Meta-Analysis. These were Based on the Newcastle-Ottawa Quality 
Assessment Scale and the QUADAS-II Guidelines 
	   Paper Author/ Year Published 
	   Cheung  et al., (1996) 
Barrett  
et al., (2012) 
Phylipsen  
et al., (2012) 
Fielding  
et al., (2013) 
Yenilmez  
et al., (2013) 
Newcastle-Ottawa 
Score 5*/8* 6*/8* 8*/8* 3*/8* 6*/8* 
QUADAS-II score Medium Medium Medium Low Medium 
Describe methods 
of patient 
selection: Describe 
included patients 
(prior testing, 
presentation, 
intended use of 
index test and 
setting) 
Laboratory setting, 
patients included 
those who were 
tested for prenatal 
diagnosis of sickle 
cell disease or β-
thalassaemia, at 
the request of the 
patients.  
Blood samples were 
collected from 
women who visited 
the Fetal Medicine 
Unit at University 
College Hospital 
NHS Foundation 
Trust, London for 
invasive diagnostic 
testing of SCD. 
DNA samples for 7 subsets of 
different populations were 
genotyped by melting curve 
analysis. 13 patients were 
selected from those who were 
sent to the laboratory for 
carrier diagnostics of SCD.  
Not described. 
Maternal 
plasma was 
extracted from 
pregnancies at 
risk of sickle 
cell disease. 
Pregnant women 
admitted to the 
Department of 
Gynecology and 
Obstetrics and 
Department of Medical 
Biochemistry for prenatal 
diagnosis during a 2-year 
period, including those 
with SCD and β-
thalassaemia mutations. 
Was a consecutive 
or random sample 
of patients 
enrolled? (Yes/ No/ 
Unclear) 
Yes Yes Yes Unclear Yes 
Was a case-control 
design avoided? 
(Yes/ No/ Unclear) 
Yes Yes Yes Unclear Yes 
Did the study avoid 
inappropriate 
exclusions? (Yes/ 
No/ Unclear) 
Unclear Unclear Unclear Unclear Unclear 
Could the selection 
of patients have 
introduced bias? 
(High/ Low/ 
Unclear) 
Low Low Low Unclear Low 
Are there concerns 
that the included 
patients do not 
match the review 
question? (High/ 
Low/ Unclear) 
Low Low Low Low Low 
Q
U
A
D
A
S-
II 
C
ri
te
ria
	  
Describe the index 
test and how it was 
conducted and 
interpreted:  
CffDNA by PCR:  
RBCs were lysed 
by boiling and 70 
rounds of PCR 
amplification, with 
a pair of 
oligonucleotide 
probes which 
detected specific 
mutations.  Single 
PCR markers 
flanked the 
mutations on 
bands of amplified 
β-globin genes. 
CffDNA analysis 
using dPCR using 
TaqMan probes to 
discriminate between 
the wild-type 
haemoglobin A and 
the mutant 
haemoglobin S 
alleles. 
CffDNA by melting curve 
analysis.  Genomic DNA was 
isolated from leukocytes by 
Auto Pure LS robotic 
workstation, which was then 
centrifuged to remove plasma 
from leukocytes. This lead to 
the extraction of DNA with 
EZ1 advanced workstation. 
Primers which amplify 12 
differet fragments on β-globin 
gene clusters covering 24 
SNPs and 20 MCA probes to 
cover the SNPs.  PAP is used 
to detect specific paternal 
allele in DNA isolated from 
maternal plasma resulting in 
primer pairs designed for 12 
SNPs. 
CffDNA 
extracted from 
maternal 
plasma was 
subsequently 
analysed by 
dPCR. 
High resolution melting 
technique and 
quantification of cffDNA 
using real-time PCR 
were used to determine 
foetal genotype from 
cffDNA extracted from 
maternal plasma.   
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Were the index test 
results interpreted 
without knowledge 
of the results of the 
reference 
standard? (Yes/ 
No/ Unclear) 
Yes Yes Yes Unclear Yes 
If a threshold was 
used, was it pre-
specified? (Yes/ 
No/ Unclear) 
Yes Yes Yes Yes Yes 
Could the conduct 
or interpretation of 
the index test have 
introduced 
bias?  (High/ Low/ 
Unclear) 
Low Low Low Low Low 
Are there concerns 
that the index test, 
its conduct, or 
interpretation differ 
from the review 
question? (High/ 
Low/ Unclear) 
Low Low Low Low Low 
Describe the 
reference standard 
and how it was 
conducted and 
interpreted:  
CVS was taken 20 
days before SCD 
cffDNA test, and 
20 days after β-
thalassemia test.  
A Reverse dot blot 
analysis allowed 
normal/ mutant 
oligonucleotides to 
be immobilised on 
a filter, amplified 
and test DNA was 
bybridised.  SCA 
only indicated 
normal 
oligonucleotides, 
therefore, no 
presence of 
disease or carrier 
status was 
identified. 
Amniocentesis was 
performed as a gold 
standard against 
which to compare 
the accuracy of the 
test. 
Foetal genomic DNA in 
question was confirmed using 
CVS testing or tested after 
birth, to confirm the PAP 
results, using direct 
sequencing analysis. 
Described as 
conventional 
genetic testing.   
Foetal DNA was tested 
against amplification 
refractory mutation 
system (ARMS)–PCR 
from samples taken by 
CVS.   
Is the reference 
standard likely to 
correctly classify 
the target 
condition? (Yes/ 
No/ Unclear) 
Yes Yes Yes Unclear Yes 
Were the reference 
standard results 
interpreted without 
knowledge of the 
results of the index 
test?  (Yes/ No/ 
Unclear) 
Yes Yes Unclear Unclear Unclear 
 
Could the 
reference standard, 
its conduct, or its 
interpretation have 
introduced bias? 
(High/ Low/ 
Unclear) 
Low Low Low Unclear Low 
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Are there concerns 
that the target 
condition as 
defined by the 
reference standard 
does not match the 
review question? 
(High/ Low/ 
Unclear) 
Low Low Low Low Low 
Describe any 
patients who did 
not receive the 
index test(s) and/or 
reference standard 
or who were 
excluded from the 
2x2 table (refer to 
flow diagram): 
Describe the time 
interval and any 
interventions 
between index 
test(s) and 
reference standard: 
It is not described 
what happened to 
the non SCD 
patients inlcuded 
in the study 
(control patients). 
Only data 
pertaining to SCD 
or β-thalassaemia 
is described.  
Interval is 
described as CVS 
was taken 20 days 
before cffDNA test 
was performed for 
SCD, and 20 days 
after the test for β-
thalassaemia. 
None stated. 
Two patients were 
unavailable for post-partum 
testing. No time intervals 
were stated. 
N/A 
All maternal blood 
samples were taken prior 
to CVS. 
Was there an 
appropriate interval 
between index 
test(s) and 
reference 
standard? 
 (Yes/ No/ Unclear) 
Yes Unclear Yes Unclear Yes 
Did all patients 
receive a reference 
standard? 
 (Yes/ No/ Unclear) 
Yes Yes No Unclear Yes 
Did all patients 
receive the same 
reference 
standard? 
 (Yes/ No/ Unclear) 
Yes Yes No Yes Yes 
Were all patients 
included in the 
analysis? 
 (Yes/ No/ Unclear) 
Yes Yes Yes Unclear Yes 
 
Could the patient 
flow have 
introduced bias?  
(High/ Low/ 
Unclear) 
Low Low Low Unclear Low 
 
retrieved, lead to the determination that it was more 
appropriate to present the data as a Forest Plot meta-
analysis (see Figure 2) indicating the proportion of 
correct diagnosis results for the use of cffDNA for the 
diagnosis of SCD in each study. The meta-analysis 
was carried out using Meta-DiSc, version 1.4 [25]. The 
proportions were compared using the DerSimonian and 
Laird approach, adapted for proportions [26]. 
RESULTS 
In order to assess how accurate or relevant the 
evidence proffered by the data collected from the 
systematic review was, the validity of the studies was 
interrogated. The evidence presented in the studies 
was deemed to be of good strength, as each paper 
described a moderate success rate. Despite some 
papers containing a smaller number of participants 
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than others, the combined research indicated that the 
use of cffDNA for NIPD for SCD has the potential for a 
high degree of accuracy and consistency [15], despite 
not yet indicating an accuracy that would allow this 
technique to be used in clinical practice. 
From the systematic review that was performed, 
four manuscripts and one abstract of a paper were 
identified to contain data on NIPD for SCD (see Table 
3). As shown in Table 3, the correct diagnosis from use 
of cffDNA to test prenatally for SCD ranged from 
76.67% to 100% (with a weighted average of 81.30%). 
However, two studies (Cheung et al., (1998) [20] and 
Phylipsen et al., (2012) [23] yielded a 100% success 
rate. These two studies were made up of two and 
thirteen test subjects respectively, therefore, the high 
percentage accuracy and low cohort size have an 
impact on the reliability of the average percentage 
accuracy of the data. That being said, the remaining 
three studies with the largest cohorts still returned an 
individual accuracy of over 75%. The incorrect data, for 
the purpose of this meta-analysis, indicates the 
incorrect and unclassified data retrieved from the 
studies. The incorrect diagnosis rate ranged from 0% to 
23.33%, with a weighted average of 18.70%. The study 
with the highest inaccuracy percentage was that by 
Yenilmez et al., (2013) [23], with 23.33% inaccuracy. 
Despite describing the correct determination of sickle 
cell mutations in 30/30 foetuses using high resolution 
melting (HRM) analysis (which was then confirmed by 
chorionic villus sampling), the technique did not 
distinguish between foetuses with SCD (7/30) and 
those with sickle cell trait (23/30). 
 
Figure 2: A Forest Plot Meta-Analysis describing the Proportion of Correct diagnoses from the data detailed in the studies 
retrieved from the systematic review. 
Table 3: Results Detailed in the Manuscripts Retrieved from the Systematic Review 
Study Name Author Correct Result  
Correct 
Diagnosis 
Incorrect 
Result* 
Incorrect 
Diagnosis*  
Prenatal diagnosis of sickle cell anaemia and thalassaemia by 
analysis of foetal cells in maternal blood 
Cheung  
et al., 1996 2/2 100.00 0 0.00 
Digital PCR Analysis of Maternal Plasma for Non-invasive 
Detection of Sickle Cell Anaemia 
Barrett  
et al., 2012 52/65 80.00 13/65 20.00 
Non-invasive prenatal diagnosis of beta-thalassaemia and sickle 
cell disease using pyrophosphorolysis-activated polymerisation 
and melting curve analysis  
Phylipsen  
et al., 2012  13/13 100.00 0 0.00 
Implementation of noninvasive prenatal diagnosis forsingle gene 
disorders into clinical practice - PCR-RED, dPCR or NGS? 
Fielding  
et al., 2013 23/29 79.31 6/29 20.69 
Non-invasive prenatal diagnosis experience in Çukurova Region 
of Southern Turkey: detecting paternal mutations of sickle cell 
anaemia and β-thalassaemia in cell-free foetal DNA using high-
resolution melting analysis 
Yenilmez  
et al., 2013 23/30 76.67 7/30 23.33 
Total Weighted Average (Percent): 81.30 18.70 
*In this table, the data classified by each of the studies as incorrect or unclassified results have been combined under one subheading of “Incorrect Result” or 
“Incorrect Diagnosis”, in order to easily distinguish between those results which produced a correct foetal diagnosis and those which did not. 
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As can be seen in Figure 2, the study by Barrett et 
al., (2012) [2] shows a smaller confidence interval than 
the study by Cheung et al., (1996) [20], due to the 
larger study size by Barrett et al., (2012) [2]. 
Furthermore, the final result of the pooled sensitivity 
indicates a result which is closest to the result from the 
study by Barrett et al., (2012) [2], thereby indicating 
that the results gained from this study describe the data 
which is closest to the true sensitivity of using cffDNA 
to test for SCD. 
DISCUSSION 
Summary of Evidence 
The analysis of data collected during the systematic 
review shows that currently NIPD for SCD achieves 
approximately 81.30% accurate diagnosis and 18.70% 
inaccurate diagnosis, which is significantly less than 
the current accuracy of the gold standard for prenatal 
testing. Therefore, extensive future research to 
enhance the accuracy of this technique will render 
invasive testing for this condition obsolete, and mitigate 
procedure related risk of miscarriage. 
Despite the use of cffDNA for NIPD for SCD having 
first been suggested over 20 years ago (as was seen 
from the study by Cheung et al., (1996) [20], there are 
very few studies detailing specific data on the accuracy 
and reliability of cffDNA as a diagnostic tool for SCD. 
As a result, out of over 3,600 papers scanned for this 
systematic review, only four full manuscripts and one 
paper abstract were found to contain any usable and 
relevant data. Therefore, the need for further research 
into this field is absolute. Further research will be able 
to design novel techniques for detection and analysis of 
cffDNA, in order to most accurately diagnose the foetal 
genotype. 
Limitations 
During the formation of this systematic review, it 
was evident that an insufficient number of clinical trials 
producing data regarding the use of NIPD for SCD 
have been undertaken, as of the date of submission of 
this study. Furthermore, there was significant 
heterogeneity with regards to the methods of cffDNA 
retrieval and testing [16] between the studies found 
during the systematic review. For example, Phylipsen 
et al., (2012) [21] and Yenilmez et al., (2013) [23] used 
SNPs to detect gene mutations, whereas Cheung et 
al., (1998) [20], Barrett et al., (2012) [2] and Fielding et 
al., (2013) [22], used PCR. Consequently, until there is 
a standardised method by which this technique is 
performed, there may be no detailed statistical analysis 
performed on the available data [16], in order to find 
the true strength of evidence present for the sensitivity 
and specificity for the use of cffDNA for NIPD of SCD 
[27], and thus generate a true odds ratio, risk ratio, 
confidence interval and p-value [16]. 
The variability between participants, interventions 
and outcomes results in clinical heterogeneity, or 
clinical diversity. The combination of the clinical 
heterogeneity, variability in study design and risk of 
bias gives rise to the statistical heterogeneity, as seen 
between the retrieved studies [16], which may cause 
inconsistencies and inaccuracies in the overall data. 
There are several factors which may contribute towards 
statistical heterogeneity of data collected between the 
studies. These include: 
• The varying quality of the studies, caused by 
discrepancies in the detailing of each of the 
studies. In particular, the abstract of a paper by 
Fielding et al., (2013) [22] had a low Newcastle-
Ottawa Quality Assessment score and 
QUADAS-II score, as it contained little 
information about the study, where as the paper 
by Phylipsen et al., (2012) [21] had very high 
quality scores, as it reported a more detailed 
description of the study; 
• The study sizes, ranging from 2 to 52 
participants in the study. The paper by Cheung 
et al., (1996) [20] only has two test subjects, 
therefore, despite 100% accuracy rating this may 
be a less accurate or reliable result when 
included in a pooled average of results; 
• The paper by Cheung et al., [20] was published 
in 1996, therefore, may use obsolete or aged 
methods for cffDNA extraction and analysis; 
• The differing methods of isolating foetal DNA 
from maternal blood and the following 
techniques for DNA analysis; 
• The differing genetic backgrounds of the 
participants and, therefore, the different genetic 
variation of SCD, which would consequently 
have different SNPs, thereby requiring different 
identification markers [21]; 
• The experiments were performed by separate 
research groups, which would result in different 
sets of random and systematic errors, and would 
subsequently alter the accuracy of the data 
collected. 
10    Global Journal of Hematology and Blood Transfusion, 2018, Vol. 5, No. 1 Short et al. 
Implications for Clinical Practice 
 These results, therefore, indicate that with further 
research, the use of cffDNA for NIPD of SCD has the 
potential to be an accurate technique for clinical 
testing, replacing the current invasive methods of 
testing, such as amniocentesis and chorionic villus 
sampling. This would diminish the potential harm 
caused to the mother and foetus during genetic testing. 
Additionally, the cost for NIPD in general is very 
expensive. It has been reported that NIPD in China 
may cost between $487 and $587, whereas 
amniocentesis costs approximately $326, and in Brazil, 
NIPD may cost $1,492, whereas amniocentesis costs 
$426, on average [25]. Therefore, unlike in countries 
with subsidised health care, such as the United 
Kingdom, it is personally very expensive for the parents 
to undergo a non-invasive procedure in order to test for 
genetic abnormalities and, therefore, this may impact 
the acceptance of this procedure to be used in the 
clinic and may deter patients from undergoing this 
procedure [25]. Furthermore, when compared to the 
cost of post-natal testing, of which reports state some 
techniques can cost as little as $0.50 per test [28], it is 
obvious that further research needs to be performed in 
order to increase efficiency of NIPD testing at a 
minimal cost, so that it may be best applied to the 
global population. 
CONCLUSION 
CffDNA for non-invasive prenatal SCD diagnosis 
appears to have the potential to be an accurate 
technique for the testing of this genetic disease, 
despite not currently indicating a proportion of correct 
diagnosis results, which would encourage the 
technique for clinical implementation. Whilst there are 
currently very limited data on the use of this technique 
for the specific testing of SCD, there is great 
opportunity for further research into the standardisation 
and clinical application of this procedure. Therefore, it 
is imperative that a reliable, sensitive and specific 
method for prenatal testing of an unborn foetus for this 
disease is developed, so the parents of the foetus can 
be prepared to deal with this lifelong disease. 
Furthermore, low cost but high quality testing without 
risking the health of the mother and unborn foetus in 
the process is absolutely necessary. The use of cffDNA 
for NIPD of SCD has the potential to be an optimal 
alternative to amniocentesis, chorionic villus sampling 
or cordocentesis with regards to accuracy, as well as 
maternal and foetal safety of these procedures, 
however, more research needs to be performed in 
order to fully determine the sensitivity and specificity of 
this test, before it can become the preferred method of 
prenatal diagnosis for SCD. 
ACKNOWLEDGEMENTS 
I would like to thank Dr Lucy Chappell for her 
contributions to the systematic review, Paul Seed for 
his statistical guidance, and Guy’s and St Thomas’ 
Charity for providing funding for wider NIPD studies 
which in turn allowed for the synthesis of this review. 
REFERENCES 
[1] Rees DC, Williams TN and Gladwin MT. Sickle-cell disease. 
The Lancet 2010; 376(9757): 2018-2031. 
https://doi.org/10.1016/S0140-6736(10)61029-X 
[2] Barrett AN, Mcdonnell TC, Chan KC and Chitty LS. Digital 
PCR analysis of maternal plasma for noninvasive detection 
of sickle cell anemia. Clinical chemistry 2012; 58(6): 1026-
1032. 
https://doi.org/10.1373/clinchem.2011.178939 
[3] Bender MA and Douthitt Seibel G. Sickle Cell Disease. In: 
RA Pagon, MP Adam, HH Ardinger, SE Wallace, A 
Amemiya, LJH. Bean, TD Bird, CT Fong, HC Mefford, RJH 
Smith and K Stephens, eds, Gene Reviews (R). Seattle 
(WA): University of Washington, Seattle 1993. 
[4] Piel FB, Hay SI, Gupta S, Weatherall DJ and Williams TN. 
Global burden of sickle cell anaemia in children under five, 
2010–2050: modelling based on demographics, excess 
mortality, and interventions. PLoS Med 2013; 10(7): 
e1001484. 
https://doi.org/10.1371/journal.pmed.1001484 
[5] NHS CHOICES, 06/16, 2016-last update [Homepage of NHS 
Choices online], [Online]. Available: http://www.nhs.uk/ 
conditions/Sickle-cell-anaemia/Pages/Introduction.aspx 
Accessed 10/2/2016. 
[6] Hassell KL. Population estimates of sickle cell disease in the 
US. American Journal of Preventive Medicine 2010; 38(4): 
S512-S521. 
https://doi.org/10.1016/j.amepre.2009.12.022 
[7] Harvard Medical School, 5/4, 2002-last update [Homepage of 
Harvard University], [Online]. Available: 
http://sickle.bwh.harvard.edu/scd_prenatal.html Accessed: 
30/1/2016. 
[8] Berry SM, Stone J, Norton ME, Johnson D, Berghella V and 
Society for Maternal-Fetal Medicine (SMFM. Fetal blood 
sampling. American Journal of Obstetrics and Gynecology 
2013; 209(3): 70-180. 
https://doi.org/10.1016/j.ajog.2013.07.014 
[9] D'souza E, Nair S, Nadkarni A, Ghosh K and Colah RB. SRY 
sequence in maternal plasma: Implications for non-invasive 
prenatal diagnosis: First report from India. Indian journal of 
human genetics 2012; 18(1): 87-90. 
https://doi.org/10.4103/0971-6866.96661 
[10] Chen JJ, Tan JA, Chua KH, Tan PC and George E. Non-
invasive prenatal diagnosis using fetal DNA in maternal 
plasma: a preliminary study for identification of paternally-
inherited alleles using single nucleotide polymorphisms. BMJ 
open 2015; 5(7): e007648-2015-007648. 
[11] Wright CF, Wei Y, Higgins JP and Sagoo GS. Non-invasive 
prenatal diagnostic test accuracy for fetal sex using cell-free 
DNA a review and meta-analysis. BMC research notes 2012; 
5: 476-0500-5-476.
NIPD for SCD Review Global Journal of Hematology and Blood Transfusion, 2018, Vol. 5, No. 1    11 
[12] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, 
Cameron C et al. The PRISMA extension statement for 
reporting of systematic reviews incorporating network meta-
analyses of health care interventions: checklist and 
explanations. Annals of Internal Medicine 2015; 162(11): 
777-784. 
https://doi.org/10.7326/M14-2385 
[13] Sotiriadis A, Papatheodorou SI and Martins WP. 
Synthesizing Evidence from Diagnostic Accuracy TEsts: the 
SEDATE guideline. Ultrasound in Obstetrics &Gynecology 
2016. 
https://doi.org/10.1002/uog.15762 
[14] Song JW and Chung KC. Observational studies: cohort and 
case-control studies. Plastic and Reconstructive Surgery 
2010; 126(6): 2234-2242. 
https://doi.org/10.1097/PRS.0b013e3181f44abc 
[15] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, 
Rennie D et al. Meta-analysis of observational studies in 
epidemiology: a proposal for reporting. Jama 2000; 283(15): 
2008-2012. 
https://doi.org/10.1001/jama.283.15.2008 
[16] University of York. Centre for Reviews and Dissemination. 
Systematic reviews: CRD's guidance for undertaking reviews 
in health care. University of York, Centre for Reviews & 
Dissemination; 2009. 
[17] NHLBI, 06/12, 2015-last update [Homepage of National 
Heart, Lung and Blood Institute], [Online]. Available: 
https://www.nhlbi.nih.gov/health/health-topics/topics/sca 
Accessed 5/3/2016. 
[18] Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, 
Reitsma JB et al. Quadas-2: a revised tool for the quality 
assessment of diagnostic accuracy studies. Annals of 
internal medicine 2011; 155(8): 529-36. 
https://doi.org/10.7326/0003-4819-155-8-201110180-00009 
[19] Wells G. SBOD. The Newcastle–Ottawa Scale (NOS) for 
assessing the Quality of non-randomised Studies in Meta-
analysis. In Proceedings or the Third Symposium on 
Systematic Reviews beyond the Basics 2000 Jul. 
[20] Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of 
sickle cell anaemia and thalassaemia by analysis of fetal 
cells in maternal blood. Nature genetics 1996; 14(3): 264-8. 
https://doi.org/10.1038/ng1196-264 
[21] Phylipsen M, Yamsri S, Treffers EE, Jansen DT, Kanhai WA, 
Boon EM, et al. Non‐invasive prenatal diagnosis of 
beta‐thalassemia and sickle‐cell disease using 
pyrophosphorolysis‐activated polymerization and melting 
curve analysis. Prenatal diagnosis 2012; 32(6): 578-587. 
https://doi.org/10.1002/pd.3864 
[22] Fielding S, Mckay F, Barrett A, Jenkins L, Lench N, Chitty 
LS. Implementation of noninvasive prenatal diagnosis for 
single gene disorders into clinical practice - PCR-RED, dPCR 
or NGS? Presented as Paper Abstracts of the ISPD 17th 
International Conference on Prenatal Diagnosis and 
Therapy. Prenat Diagn 2013; 33(1): 1-26. 
[23] Yenilmez ED, Tuli A and Evrüke İC. Noninvasive prenatal 
diagnosis experience in the Çukurova Region of Southern 
Turkey: detecting paternal mutations of sickle cell anemia 
and β‐thalassemia in cell‐free fetal DNA using high‐resolution 
melting analysis. Prenatal diagnosis 2013; 33(11): 1054-
1062. 
https://doi.org/10.1002/pd.4196 
[24] Crombie I and Davies H. 2009-last update [Homepage of 
Hayward Medical Communications], [Online]. Available: 
http://www.medicine.ox.ac.uk/bandolier/painres/download/wh
atis/meta-an.pdf Accessed: 15/4/ 2016. 
[25] Chandrasekharan S, Minear MA, Hung A and Allyse M. 
Noninvasive prenatal testing goes global. Science 
translational medicine 2014; 6(231): 231fs15. 
https://doi.org/10.1126/scitranslmed.3008704 
[26] Zamora J, Abraira V, Muriel A, Khan K and Coomarasamy A. 
Meta-DiSc: a software for meta-analysis of test accuracy 
data. BMC medical research methodology 2006; 6(1): 1. 
https://doi.org/10.1186/1471-2288-6-31 
[27] Haidich A. Meta-analysis in medical research. Hippokratia 
2011; 14(1): 9-37. 
[28] Kumar AA, Chunda-Liyoka C, Hennek JW, Mantina H, Lee 
SR, Patton MR et al. Evaluation of a density-based rapid 
diagnostic test for sickle cell disease in a clinical setting in 
Zambia. PloS one 2014; 9(12): e114540. 
https://doi.org/10.1371/journal.pone.0114540 
 
Received on 15-08-2017 Accepted on 18-12-2017 Published on 15-01-2018 
 
http://dx.doi.org/10.15379/2408-9877.2018.05.01.01 
© 2018 Short et al.; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
 
 
